Welcome to our dedicated page for SOPHiA GENETICS SA SEC filings (Ticker: SOPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SOPHiA GENETICS SA filings document the disclosures of a foreign private issuer that reports through Form 6-K and related registration statements. The company’s filings include unaudited interim condensed consolidated financial statements, management discussion and analysis, press releases on operating results, and Swiss annual report materials tied to its AI-driven precision medicine software business.
Other filings cover annual general meeting notices, proxy materials, shareholder voting documents, incorporation by reference into Form F-3 and Form S-8 registration statements, and capital-structure matters such as credit-agreement amendments, term loan commitments, warrants, and ordinary-share purchase rights.
SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported small insider sales tied to tax obligations. On July 6, 2026, he sold a total of 216 Ordinary Shares in open-market transactions at prices between $5.0251 and $5.0862 per share.
According to the footnotes, these were non-discretionary “sell to cover” trades executed to satisfy taxes from restricted stock units that vested on July 2 and July 3, 2026. After these transactions, he continues to hold 147,948 Ordinary Shares directly.
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu sold 7,393 ordinary shares of the company on July 6, 2026 at a weighted average price of $5.1611 per share. According to the disclosure, these open-market sales were made to satisfy tax withholding obligations from restricted stock units that vested on July 2 and July 3, 2026, and were executed under a pre-established Rule 10b5-1(c) trading plan, meaning they were not discretionary trades. After the sale, Menu directly holds 233,387 ordinary shares, indicating he maintains a substantial ongoing equity position in the company.
SOPHiA GENETICS SA Executive Chairman Jurgi Camblong reported an open-market sale of 22,486 Ordinary Shares at a weighted average price of $5.255 per share. According to the filing, the sale was made to satisfy tax withholding obligations from restricted stock unit vesting and was executed under a pre-established Rule 10b5-1(c) trading plan, described as non-discretionary. After this transaction, he directly holds 3,558,807 Ordinary Shares.
SOPH affiliate reports planned and completed share sales under Form 144, including multiple 10b5-1 sales. The notice lists proposed securities to be sold of 15,000 Restricted Stock Units (07/03/2025) and 10,000 Pre-IPO shares (02/02/2020). The filing also documents numerous 10b5-1 sales by Philippe Menu between 04/07/2026 and 06/25/2026, with individual sale amounts reported per trade.
SOPH filer submitted a Form 144 notice reporting resale activity and recent 10b5-1 sales of Common Stock by a holder identified as ZHENYU XU. The excerpt lists multiple 10b5-1 sales executed between 04/07/2026 and 06/15/2026, including trades of 4,000 and smaller lots with reported proceeds.
The filing also lists 7,393 Restricted Stock Units dated 07/02/2026 and 12,000 Founders Shares dated 06/20/2012 as securities referenced in the submission.
Morgan Stanley Smith Barney LLC submitted a Form 144 reporting proposed and completed affiliate sales of Common Stock and planned sale of Restricted Stock Units. The filing lists three 10b5-1 sale transactions by George Cardoza: 2,413 shares for $11,768.44 on 04/07/2026, 1,403 shares for $6,800.65 on 04/08/2026, and 774 shares for $4,163.73 on 06/22/2026. The filing also shows 1,592 Restricted Stock Units to be sold on 07/02/2026.
Company: SOPH. This Form 144 notifies proposed sales of Restricted Stock Units and reports recent 10b5-1 sales by an affiliate. The filing lists 9,838 RSUs as the security to be sold and shows multiple completed 10b5-1 sale trades in April–June 2026 with individual amounts and proceeds reported.
The reported 10b5-1 transactions include trades such as 4,442 shares for $21,166.13 on 04/13/2026 and smaller lots through 06/22/2026. The filing is a routine affiliate resale notice under Form 144; cash‑flow treatment and ultimate sale timing are those described by the reporting person’s plans.
Common shares were reported in a Form 144 filing showing a series of 10b5-1 sales by Manuela Valente. The excerpt lists four sale entries on 04/07/2026, 04/08/2026, 04/20/2026, and 05/19/2026 with per‑trade share amounts and proceeds recorded.
The filing also lists Restricted Stock Units dated 07/02/2026 under the issuer designation; other proceeds treatment and aggregate totals are not stated in the provided excerpt.
SOPHiA GENETICS SA Executive Chairman Jurgi Camblong reported both option exercises and share sales in late June. On June 29–30, he sold a total of 83,679 Ordinary Shares in multiple open‑market transactions at prices including $6.30, $6.0215, $6.00 and $5.8670 per share, under a pre‑arranged Rule 10b5‑1(c) trading plan.
He also exercised share options to acquire 63,479 Ordinary Shares at an exercise price of $3.16 per share, converting previously granted options into stock. After these transactions, he directly holds 3,581,293 Ordinary Shares and continues to hold 4,646,057 derivative stock options across remaining grant tranches, indicating a substantial ongoing exposure to the company’s equity despite the sales.
SOPH filing: proposed sale of up to 70,000 shares by an affiliate via registered broker-dealer transactions. The notice lists 50,000 shares from an exercise of stock options (06/30/2026) and 20,000 founders shares (03/18/2021). The excerpt also shows multiple Rule 10b5-1 sales executed by Jurgi Camblong during April–June 2026, including 18,410 shares on 06/29/2026 and 50,069 shares on 06/26/2026.
Transactions are reported through Morgan Stanley Smith Barney LLC as broker-dealer. Timing and aggregate proceeds are recorded per sale rows in the excerpt.